Which is better for CV risk in RA:
triple therapy DMARDs or TNFi?
TARGET study
n=159 using PET/CT surrogate (endpoint responsivenessđź‘€)
- either led to benefit
- both equally good
- benefit *not* linked to change in DAS28
A direct CV effect of RA Rx?
ABST2215 #ACR22 @RheumNow https://t.co/4FPvSbfGsD
Links:
14-11-2022